On February 13, 2015, the U. S. Food and Drug Administration approved lenvatinib (LENVIMA) for the treatment of patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer.
On February 13, 2015, the U. S. Food and Drug Administration approved lenvatinib (LENVIMA) for the treatment of patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer.
AMERICAN THYROID ASSOCIATION® , ATA® , THYROID® , CLINICAL THYROIDOLOGY® , and the distinctive circular logo are registered in the U.S. Patent and Trademark Office as trademarks of the American Thyroid Association® , Inc.© 2025 American Thyroid Association.
